IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.133
NA - Nord America 2.684
AS - Asia 2.528
SA - Sud America 766
AF - Africa 110
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 3
Totale 9.233
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.590
IE - Irlanda 1.348
SG - Singapore 1.119
HK - Hong Kong 641
BR - Brasile 615
RU - Federazione Russa 549
VN - Vietnam 327
SE - Svezia 315
DE - Germania 245
UA - Ucraina 242
IT - Italia 202
CN - Cina 188
FI - Finlandia 64
BJ - Benin 59
AR - Argentina 56
IN - India 55
GB - Regno Unito 54
ID - Indonesia 48
CA - Canada 46
EC - Ecuador 36
KR - Corea 33
MX - Messico 33
BD - Bangladesh 24
ZA - Sudafrica 19
CO - Colombia 18
NL - Olanda 18
FR - Francia 17
JP - Giappone 17
AT - Austria 16
PL - Polonia 13
CL - Cile 12
EG - Egitto 12
IQ - Iraq 12
PE - Perù 10
CZ - Repubblica Ceca 9
ES - Italia 9
IR - Iran 9
LT - Lituania 9
PY - Paraguay 9
TR - Turchia 9
KE - Kenya 7
PK - Pakistan 7
UZ - Uzbekistan 7
VE - Venezuela 7
AE - Emirati Arabi Uniti 6
EU - Europa 6
SA - Arabia Saudita 5
MA - Marocco 4
AU - Australia 3
BE - Belgio 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
GR - Grecia 3
PT - Portogallo 3
RO - Romania 3
TN - Tunisia 3
BN - Brunei Darussalam 2
BO - Bolivia 2
EE - Estonia 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
PA - Panama 2
PS - Palestinian Territory 2
SI - Slovenia 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CH - Svizzera 1
CI - Costa d'Avorio 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
YE - Yemen 1
Totale 9.233
Salva come PNG Salva come JPEG
Città #
Dublin 1.344
Hong Kong 641
Jacksonville 296
Singapore 260
Moscow 196
Wilmington 195
Ashburn 179
Lawrence 174
Princeton 174
San Mateo 145
Chandler 130
Ho Chi Minh City 121
Los Angeles 102
Beijing 90
Dearborn 84
Buffalo 73
Dallas 64
Hanoi 62
Cotonou 59
São Paulo 51
Redondo Beach 48
Seoul 33
New York 31
Novara 28
Piemonte 28
Boardman 27
Bremen 26
Rio de Janeiro 25
Houston 24
Ann Arbor 23
Helsinki 22
Fairfield 19
Haiphong 18
Tokyo 17
Toronto 17
Brasília 16
Falkenstein 16
Montreal 16
Brooklyn 15
Norwalk 15
Andover 14
Des Moines 14
Chennai 13
Nuremberg 13
Quito 13
Woodbridge 13
Da Nang 12
Frankfurt am Main 12
Milan 12
Santa Clara 12
Warsaw 12
Denver 11
Stockholm 11
Atlanta 10
Curitiba 10
Johannesburg 10
London 10
Thái Bình 10
Vienna 10
Brno 9
Munich 9
Poplar 9
Porto Alegre 9
Tianjin 9
Amsterdam 8
Biên Hòa 8
Boston 8
Jakarta 8
Mexico City 8
Mülheim 8
Querétaro 8
Turin 8
Guayaquil 7
Hải Dương 7
Menlo Park 7
Mumbai 7
Orem 7
Seattle 7
Sorocaba 7
Tashkent 7
Assago 6
Belo Horizonte 6
Campinas 6
Florianópolis 6
Lima 6
Ninh Bình 6
Phoenix 6
Salvador 6
Santo André 6
Asunción 5
Bologna 5
Buenos Aires 5
Chicago 5
Goiânia 5
Grafing 5
Hefei 5
Juiz de Fora 5
Lấp Vò 5
Manaus 5
Manchester 5
Totale 5.400
Salva come PNG Salva come JPEG
Nome #
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 111
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 103
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 103
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 99
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 94
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 93
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 88
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 87
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 87
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 85
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 83
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 83
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 82
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 81
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 79
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 79
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 79
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 77
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 77
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 77
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 75
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 75
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 74
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 70
Genetic and phenotypic attributes of splenic marginal zone lymphoma 70
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 67
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 67
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 66
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 66
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 63
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 62
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 62
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 62
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 61
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 60
Controversies in the treatment of follicular lymphoma 59
Droplet Digital PCR Assay for MYD88L265P 58
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 58
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 57
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 57
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 56
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 56
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 55
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 55
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 55
The adulthood of MRD detection in MCL 55
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 55
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 54
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 54
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 53
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 52
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 52
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 51
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 51
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 51
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 50
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 50
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 50
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 49
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 49
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 49
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 49
The black swan: a case of central nervous system graft-versus-host disease 48
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 48
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 48
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 47
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 47
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma 47
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 47
The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma 47
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 47
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 46
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 46
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 46
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 46
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission 46
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 46
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 46
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 46
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 45
EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas 45
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 45
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 45
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 44
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 44
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 44
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 44
Home management of hematological patients requiring hospital admission 44
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 44
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 43
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma 43
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 43
Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 43
Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 43
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft 43
Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 43
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi 43
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition 42
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy 42
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 42
Totale 5.895
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.667
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021525 0 0 0 0 0 5 100 88 159 6 158 9
2021/2022794 4 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20262.653 165 212 578 1.113 537 48 0 0 0 0 0 0
Totale 9.509